Disease/Infection News

RSS

Malaria vaccine close to reality

A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Quick-Med Technologies, Inc.a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today its NIMBUS and Stay Fresh antimicrobial technologies will be highlighted at the 2010 Clinical Symposium on Advances in Skin and Wound Care, to be held in Orlando, Florida from September 30 – October 3, 2010.

29 Sep 2010

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus (RSV) infections.

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Significant progress made universally in increasing access to HIV/AIDS services: Report

Significant progress has been made in several low- and middle-income countries in increasing access to HIV/AIDS services, according to a new report released today. The report Towards universal access by WHO, the United Nations Children's Fund and the Joint United Nations Programme on HIV/AIDS is the fourth annual report for tracking progress made in achieving the 2010 target of providing universal access to HIV prevention, treatment and care.

29 Sep 2010

Report shows continuing progress in scaling up global HIV/AIDS interventions

The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.

29 Sep 2010

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

As teens and twenty-somethings returned to school this month, many obsessed about their appearance, especially those with moderate to severe acne. A new screening test might save the day.

29 Sep 2010

Outbreak of whooping cough mirrors challenges in developing world, global health official says

The outbreak of whooping cough in Texas, California, and other states this year underscores the critical importance of widespread vaccination coverage, both locally as well as around the world, said a leading global health official attending conferences on world affairs and immunization in Fort Worth this week.

29 Sep 2010

MRSA survivors to share experience at World MRSA Day kickoff event

No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.

29 Sep 2010

Malaria vaccine development meeting begins in Washington

Agence France-Presse reports on a malaria vaccine development meeting that kicks off Tuesday in Washington, D.C.One of the stars at the meeting will be the RTS,S malaria vaccine, which has been developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative, with funding from the Bill & Melinda Gates Foundation, the news service writes.

29 Sep 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

HIV care providers call Senate leaders to support Pennsylvania Legislation on HIV testing

HIV care providers from across the state today called upon key Senate leaders to support pending legislation that would change the current Pennsylvania law on HIV testing by removing the requirement for written informed consent and pre-test counseling.

29 Sep 2010

New topical microbicide gel can prevent HIV transmission

Amyloid protein structures are best known for the troubles they pose in the brains of Alzheimer's patients. Now researchers are trying to exploit their presence in a very different place in semen to find a new way to stop HIV.

29 Sep 2010

Teens who experience manic phase of bipolar disorder more likely to engage in high risk sexual behaviors

Although research has shown that teens with mental health disorders are more likely to engage in high risk sexual behaviors, like unprotected sex, a new study from the Bradley Hasbro Children's Research Center suggests there is an additional risk associated with certain psychiatric diagnoses.

29 Sep 2010

Researchers unveil mechanism of candida infections

More than half of all people are hosts to Candida albicans in their bodies. This species might be located on their skin or mucous membranes or in the intestines frequently without causing any symptoms. However, it can be dangerous to patients whose immunological system has been weakened such as after organ transplants or chemotherapy with cancer. Then, this fungus penetrates into deeper layers of tissue and uses the blood system to spread throughout the body. In Germany alone, several thousand people die from systemic candida infections every year.

29 Sep 2010

People with pet allergies develop ragweed allergy symptoms: Research

Researchers found that people with pet allergies often develop ragweed allergy symptoms more quickly than others. But the study also suggests that once allergy season is in full swing, those symptom differences subside.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

FDA issues warning letters to three companies for claiming plaque removal by mouth rinse products

The FDA today issued warning letters to three companies that manufacture and market mouth rinse products with claims that they remove plaque above the gum line or promote healthy gums. These claims suggest the products are effective in preventing gum disease when no such benefit has been demonstrated.

29 Sep 2010

Disease/Infection News

Malaria vaccine close to reality

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Significant progress made universally in increasing access to HIV/AIDS services: Report

Report shows continuing progress in scaling up global HIV/AIDS interventions

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

Outbreak of whooping cough mirrors challenges in developing world, global health official says

MRSA survivors to share experience at World MRSA Day kickoff event

Malaria vaccine development meeting begins in Washington

CAP cells produce high virus titers upon influenza strain infection

HIV care providers call Senate leaders to support Pennsylvania Legislation on HIV testing

New topical microbicide gel can prevent HIV transmission

Teens who experience manic phase of bipolar disorder more likely to engage in high risk sexual behaviors

Researchers unveil mechanism of candida infections

People with pet allergies develop ragweed allergy symptoms: Research

Early initiation of ART may prevent immune system damage in HIV patients: Study

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

FDA issues warning letters to three companies for claiming plaque removal by mouth rinse products

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News